 |
|
|
| |
Low Rates of Integrase Resistance for Elvitegravir and Raltegravir through Week 96 in the Phase 3 Clinical Study GS-US-183-0145
|
| |
| |
Reported by Jules Levin
IAC July 22-27 2012 Wash DC
NA Margot, MS Rhee, J Szwarcberg, and MD Miller
Gilead Sciences, Inc., Foster City, CA, USA
|
| |
|
|
|
|
|
